<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048737</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-233</org_study_id>
    <nct_id>NCT00048737</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies</brief_title>
  <official_title>Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to see if low intensity chemotherapy given
      together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem
      cells from a donor can increase the length of remission in patients with leukemia and
      lymphoma. The safety of this treatment will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rituxan is an antibody made from human and mouse protein. It reacts with a certain antigen on
      lymphoma cells and causes the body's immune system to destroy the lymphoma cells. 90Y Zevalin
      and 111In Zevalin are murine-based antibodies combined with a radioactive agent that can also
      destroy lymphoma cells. Unlike Rituxan, 90Y Zevalin cannot be traced by regular scanning and
      requires indium to determine its distribution through the body.

      Before treatment starts, patients will have a physical exam, including blood tests and urine
      tests. Women who are able to have children must have a negative blood pregnancy test. Bone
      marrow samples will be taken. For bone marrow sampling, a large needle is placed in the
      hipbone after it has been numbed. The bone marrow is then withdrawn through the needle.
      Patients will have a chest x-ray, computed tomography (CT) scans, an EKG, and tests of lung
      function.

      Blood tests, urine tests, bone marrow sampling, and x-rays will be done as needed to track
      the effects of the transplant. Patients will have transfusions of blood and platelets as
      needed. Blood tests will be done daily while patients are in the hospital.

      Patients in this study will receive an unlabeled antibody form of Y2B8 called rituxan by vein
      followed by a dose of 111In Zevalin by vein. 111In Zevalin includes the radioactive agent
      indium, which shows up when patients have x-rays or scans. The scans can show where and how
      fast the drug travels in the body and how long the drug stays in the body. Doctors need to be
      able to see how much of the drug goes to the tumor and how much goes to normal organs to see
      if it is safe to give 90Y Zevalin on an outpatient basis. A scan will be taken 48 to 72 hours
      after 111In Zevalin is given.

      If the radiation in the 111In Zevalin is not a threat to normal organs and bone marrow,
      patients may receive 90Y Zevalin. Seven days after the 111In Zevalin injection, patients will
      receive a second dose of rituxan followed by a dose of 90Y Zevalin.

      Patients will also receive fludarabine and cyclophosphamide daily for 3 days. All of the
      chemotherapy drugs will be given through a catheter (plastic tube) that extends into the
      large chest vein. The catheter will be left in place throughout treatment. When chemotherapy
      is finished, blood stem cells from a donor will be given through the catheter. Granulocyte
      colony-stimulating factor (G-CSF or GCSF), a hormone that helps the production of blood
      cells, will be injected under the skin once a day until the neutrophil counts recover in the
      blood. Patients will receive methotrexate for 3 days post transplant and tacrolimus for 6
      months or more to prevent graft versus host disease.

      All patients will have complete checkups, including blood and urine tests 2 or 3 times during
      the first 12 weeks of the study. Tumors will be measured by CT or MRI and gallium scans.
      Patients will be asked to fill out a survey about quality of life issues (maintaining normal
      routine, family life, social life, pain). It takes about half an hour to fill out the survey.
      A bone marrow sample may be taken. A test of heart function will be done. Checkups and tests
      will be done every 3 months for 1 year and then every 6 months for 4 more years.

      Treatment will be given in the hospital at M. D. Anderson. Patients will need to stay in the
      hospital for about 3 to 4 weeks. Patients must stay in the Houston area for about 100 days
      after the transplant. After that, patients will need to return to Houston from time to time
      for blood tests, urine tests, and other exams.

      This is an investigational study. 90Y-Zevalin is approved by the FDA for relapsed and
      refractory lymphoma. Its use in this trial, however, is investigational. About 70 patients
      will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Graft Failure</measure>
    <time_frame>100 days</time_frame>
    <description>Graft failure is defined as either lack of hematologic recovery or lack of or loss of detectable donor cells.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>90Y Zevalin in ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zevalin Radioimmunotherapy</intervention_name>
    <description>Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg</description>
    <arm_group_label>90Y Zevalin in ASCT</arm_group_label>
    <other_name>90Y Zevalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>250 mg/m^2 on day 1 and day 8</description>
    <arm_group_label>90Y Zevalin in ASCT</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m^2/day for 3 days</description>
    <arm_group_label>90Y Zevalin in ASCT</arm_group_label>
    <other_name>Fludarabine phosphate</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals</description>
    <arm_group_label>90Y Zevalin in ASCT</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Stem Cell Transplantation</intervention_name>
    <description>Allogeneic stem cell transplantation 2 days after chemotherapy</description>
    <arm_group_label>90Y Zevalin in ASCT</arm_group_label>
    <other_name>ASCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients in relapse or considered at high risk for relapse or refractory
             CD-20-positive B-cell NHL or CLL. Patients considered for high risk of relapse are
             patients who do not achieve complete response (CR) with frontline chemotherapy, CLL is
             Richter's and CLL with high risk chromosomal abnormalities.

          2. Measurable disease.

          3. Age 18-70 years, expected survival &gt;/= 3 months, performance status 0 to 2.

          4. Availability of a matched related donor.

          5. &lt;/+ 50% bone marrow involvement.

          6. CLL with &lt;/+ 10,000 circulating lymphocytes.

          7. Availability of a matched related or unrelated donor.

        Exclusion Criteria:

          1. Prior myeloablative therapies or radioimmunotherapy.

          2. Prior external beam radiation therapy to &gt;25% of active bone marrow.

          3. Prior therapy with 90Y Zevalin or Campath.

          4. CNS lymphoma, HIV, HTLV-1 positivity, some creatinine &gt;1.6 mg/dl or serum bilirubin
             &gt;1.5 mg/dl.

          5. Pregnancy or lactation.

          6. Symptomatic pulmonary or cardiac disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issa F. Khouri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center official website</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2002</study_first_submitted>
  <study_first_submitted_qc>November 7, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2002</study_first_posted>
  <results_first_submitted>April 22, 2013</results_first_submitted>
  <results_first_submitted_qc>June 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2013</results_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoid Malignancy</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Neosar</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Fludarabine Phosphate</keyword>
  <keyword>Fludara</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituxan</keyword>
  <keyword>Zevalin</keyword>
  <keyword>Indium Zevalin</keyword>
  <keyword>90Y Zevalin</keyword>
  <keyword>CD-20-positive</keyword>
  <keyword>B-cell Lymphoma</keyword>
  <keyword>CD-20-positive B-cell Lymphoma</keyword>
  <keyword>NHL</keyword>
  <keyword>CLL</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Allogeneic Stem Cell Transplantation</keyword>
  <keyword>ASCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: October 30, 2002 to September 21, 2010. All participants were recruited at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>90Y Zevalin in ASCT</title>
          <description>Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.
Rituximab : 250 mg/m^2 on day 1 and day 8
Allogeneic Stem Cell Transplantation : Allogeneic stem cell transplantation 2 days after chemotherapy
Cyclophosphamide : 750 mg/m^2/day x 3, given on the same days as fludarabine, at 4-hour intervals
Zevalin Radioimmunotherapy : Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
Fludarabine : 30 mg/m^2/day x 3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>90Y Zevalin in ASCT</title>
          <description>Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.
Rituximab : 250 mg/m^2 on day 1 and day 8
Allogeneic Stem Cell Transplantation : Allogeneic stem cell transplantation 2 days after chemotherapy
Cyclophosphamide : 750 mg/m^2/day x 3, given on the same days as fludarabine, at 4-hour intervals
Zevalin Radioimmunotherapy : Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
Fludarabine : 30 mg/m^2/day x 3</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Graft Failure</title>
        <description>Graft failure is defined as either lack of hematologic recovery or lack of or loss of detectable donor cells.</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>90Y Zevalin in ASCT</title>
            <description>Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.
Rituximab: 250 mg/m^2 on day 1 and day 8
Allogeneic Stem Cell Transplantation : Allogeneic stem cell transplantation 2 days after chemotherapy
Cyclophosphamide : 750 mg/m^2/day x 3, given on the same days as fludarabine, at 4-hour intervals
Zevalin Radioimmunotherapy : Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
Fludarabine : 30 mg/m^2/day x 3</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Failure</title>
          <description>Graft failure is defined as either lack of hematologic recovery or lack of or loss of detectable donor cells.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 Years and 1 Month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>90Y Zevalin in ASCT</title>
          <description>Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.
Rituximab : 250 mg/m^2 on day 1 and day 8
Allogeneic Stem Cell Transplantation : Allogeneic stem cell transplantation 2 days after chemotherapy
Cyclophosphamide : 750 mg/m^2/day x 3, given on the same days as fludarabine, at 4-hour intervals
Zevalin Radioimmunotherapy : Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
Fludarabine : 30 mg/m^2/day x 3</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description># of participants affected-1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>C-Diff Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Death due to G.I. GVHD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Death Due to Chronic Liver/G.I GVHD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Right Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Viral Hepatitis B reactivation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Prolonged Hospitalization, Generalized Weakness/Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>secondary malignancy- Melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Secondary Malignancy-Early Nodular Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Low Ejection Fraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="61" subjects_affected="61" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Elevated Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Increased Bilirubin</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Increased LDH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="88" subjects_affected="37" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuoropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Altered Mood</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Altered Mood-Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Skin Dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Issa Khouri, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>rvalverde@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

